Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
Anlotinib, when added onto EGFR TKI therapy following gradual progression or oligo-progression, conferred significant PFS benefits upon <i>EGFR</i> mutant NSCLC patients, supporting adding anlotinib to ongoing first-line EGFR TKI therapy for oligoprogressive disease.
Authors
- Fei Zhou (ORCID: https://orcid.org/0000-0002-5865-0052)
- Guilin Zeng
- Kangwu Wang
- Minglei Zhuo (ORCID: https://orcid.org/0000-0003-2489-7791)
- Nong Yang (ORCID: https://orcid.org/0000-0003-0997-3645)
- Zhengxiang Han (ORCID: https://orcid.org/0000-0003-2463-8933)
- Dabing Huang
- Jun Li (ORCID: https://orcid.org/0000-0002-8664-4813)
- Ling Li (ORCID: https://orcid.org/0000-0002-1642-142X)
- Jian Chen (ORCID: https://orcid.org/0000-0002-5567-2280)
- Hongmin Wang (ORCID: https://orcid.org/0000-0002-0392-4458)
- Jisheng Li (ORCID: https://orcid.org/0000-0003-3061-8998)
- Caicun Zhou (ORCID: https://orcid.org/0000-0002-7095-0381)
- Jin Shi (ORCID: https://orcid.org/0000-0002-5148-9075)
- Fengming Ran
- Jinghui Bai
- Yang Song (ORCID: https://orcid.org/0009-0002-4380-2065)
Institutions
- Qingdao University (CN)
- University of Science and Technology of China (CN)
- Xuzhou Medical College (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Yuhuangding Hospital (CN)
- Peking University Cancer Hospital (CN)
- Second People Hospital of Hunan (CN)
- Guangzhou First People's Hospital (CN)
- Shanghai East Hospital (CN)
- Chengdu Fifth People's Hospital (CN)
- Tengzhou Central People's Hospital (CN)
- Xian Yang Central Hospital (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Tongji Hospital (CN)
- Hubei Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Qilu Hospital of Shandong University (CN)
- Guangzhou Medical University (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fphar.2025.1686364
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00